Professor Jerome Boursier played a leading role in a multi-center study evaluating non-invasive tests (NITs) for fibrotic MASH, published in JHEP Reports. This study addresses a critical challenge in MASH therapeutic trials, where 70-80% of candidates fail screening due to the absence of fibrotic MASH on baseline liver biopsies.
The research, conducted with an esteemed team including Jeanne Fichez, Thomas Mouillot, Luisa Vonghia, Charlotte Costentin, Clémence Moreau, Marine Roux, Adèle Delamarre, Sven Francque, Ming-Hua Zheng, and others, compared eight NITs across 1,005 patients with histologically proven MASLD. Three specialized NITs designed for fibrotic MASH—FNI, MACK-3, and FAST demonstrated superior accuracy over commonly used tests for advanced fibrosis.
Professor Boursier’s expertise in non-invasive hepatology diagnostics was instrumental in shaping the study’s methodology, data analysis, and clinical interpretation. The findings highlight that a sequential combination of NITs (FAST → Agile3+, MACK-3 → ELF) significantly improves patient selection for MASH therapeutic trials, reducing false positives while maintaining diagnostic accuracy.
The contributions of Professor Boursier and his colleagues will have a lasting impact on the field of hepatology, paving the way for more efficient and targeted MASH treatments.
Read more: https://lnkd.in/eKrzFdFc
